Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

ChinaBio® Today Exclusive: Licensing agreement between Laekna Inc. and a Major Pharmaceutical Company

publication date: Jul 9, 2017
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Laekna, Inc, a biotechnology company, announced today that it acquires world-wide rights from Novartis for an CYP17 inhibitor (CFG920) for the treatment of prostate cancer.  CFG920 is an oral drug candidate of androgen inhibitor. Novartis has conducted a clinical “proof of concept” study in metastatic castration resistant prostate cancer patients and received positive results. More details....



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login